Articles

Myelofibrosis patients refractory to JAK inhibitor therapy typically have poor prognosis. Pelabresib demonstrates improvement in clinical outcomes while maintaining an acceptable safety profile in this patient subset. Read More ›

Patients with myelofibrosis who are refractory to JAK inhibitors often lack safe and effective treatment options. Selinexor may slow disease progression by reducing growth of malignant myelofibrosis cells. Read More ›

Ruxolitinib is an approved therapy for myelofibrosis but some patients experience serious side effects. Fedratinib is an effective therapeutic option for these patients without development of severe adverse events. Read More ›

Anemia is a common side effect in many patients with myelofibrosis on ruxolitinib therapy. Phase 2 clinical trial data demonstrate mitigation of anemia indices in this patient population by sotatercept. Read More ›

On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review. Read More ›

Poor response on subsequent therapies is typically seen in patients with relapsed/refractory multiple myeloma (RRMM) who have had 3 prior lines of therapy with immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies. In addition, challenges for future treatment options are presented. Read More ›

Recent studies have illustrated complete response (CR) rates >50% for transplant-eligible patients with multiple myeloma (MM) treated with optimized induction followed by high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT). However, many patients relapse early. Patients who relapse are generally thought to have very low survival rates. Read More ›

According to data from the phase 2 FORTE trial, 3 different techniques were analyzed and compared to characterize minimal residual disease (MRD), including positron emission tomography/computed tomography (PET/CT), multiparameter flow cytometry (MFC), and next-generation sequencing (NGS). Read More ›

The combination of carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone (KRd) as induction therapy does not improve outcomes in patients newly diagnosed with multiple myeloma compared with the current standard of care with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd). Read More ›

Cellular therapy is becoming an attractive option for heavily pretreated patients with relapsed or refractory multiple myeloma. According to data presented at the ASCO 2020 virtual annual meeting, 2 chimeric antigen receptor (CAR) T-cell drugs have generated impressive rates of response that are sustainable. Read More ›